- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Yatharth Hospital gets SEBI green signal to launch Rs 610 crore IPO
In Sebi's parlance, issuing an observation letter implies its go-ahead to float an IPO.
New Delhi: Yatharth Hospital & Trauma Care Services Ltd has received capital markets regulator Sebi's go ahead to float an initial public offering (IPO).
The company operates three super specialty hospitals in Delhi-NCR. It recently expanded to Madhya Pradesh.
Yatharth Hospital's IPO consists of a fresh issue of equity shares aggregating up to Rs 610 crore and an Offer For Sale (OFS) offer for sale of up to 65.51 lakh equity shares by the company's promoters and promoter group entities, according to the draft red herring prospectus (DRHP).
Read also: PharmEasy parent API Holdings and 2 others get SEBI go-ahead to float IPOs
The company, which filed its preliminary IPO papers with the capital markets regulator in April, obtained its "observation" letter on August 2, an update with the Securities and Exchange Board of India (Sebi) showed.
In Sebi's parlance, issuing an observation letter implies its go-ahead to float an IPO.
Read also: Macleods Pharma and 2 others get SEBI go ahead for IPOs
Going by the draft papers, the firm intends to utilise the net proceeds for payment of debt, funding capital expenditure expenses, funding inorganic growth initiatives through acquisition and other strategic initiatives, and for general corporate purposes.
Intensive Fiscal Services Pvt Ltd, Ambit Pvt Ltd and IIFL Securities Ltd are the book-running lead managers for the IPO.
Read also: Innova Captab files IPO papers with SEBI
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751